FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328105353> ?p ?o ?g. }

• W4328105353 endingPage "86" @default.
• W4328105353 startingPage "80" @default.
• W4328105353 abstract "Background Among patients with peripheral artery disease (PAD), depression is diagnosed in 17–25% and negatively impacts wound healing, quality of life, and survival. We hypothesized that depression is underdiagnosed in patients with PAD. Additionally, given the associations between depression and mortality in PAD patients, there is an increased need to investigate the strength of this relationship. The present analysis includes 2 studies to address the following aims: (1) Investigation of the prevalence of concomitant PAD and depression in a cohort from the Southeastern United States, and (2) Examination of the association between depression and all-cause mortality in a cohort of Canadian patients with PAD. Methods STUDY 1: From June–August 2022, the Patient Health Questionnaire Module 9 (PHQ-9) was administered to all patients seeking PAD-related care including medical, wound/podiatric, or vascular interventional/surgical treatment, in the University of North Carolina-Chapel Hill Vascular, Wound, and Podiatry clinics. The PHQ-9 assesses symptoms over 2 weeks and is scored 0–27, with higher scores indicating increasingly severe depression. Demographics, primary diagnosis, depression history, and antidepressant prescription were determined through chart review. We compared the proportion of positive depression screenings (PHQ-9 ≥ 5) to known depression. Among those treated for depression, the PHQ-9 score severity was evaluated. T-tests and χ2 tests were used to compare means and proportions. STUDY 2: From July 2015 to October 2016, the Geriatric Depression Scale Short Form was administered to adult patients with PAD undergoing revascularization. The Geriatric Depression Scale Short Form is a self-report measure of depression with a score >5 consistent with depression. The prevalence of depression was determined; primary outcome was all-cause mortality at 6 months. Results STUDY 1: In 104 PAD patients (mean age 66.6 ± 11.3 years, 37% female), 37% of respondents scored ≥5 on the PHQ-9 survey, indicating at least mild depression. Only 18% of PAD patients had a history of depression, demonstrating a significant difference between the PHQ-9 findings and documented medical history. While depression was underdiagnosed in both men and women, men were more likely to have unrecognized depression (chi-squared statistic = 35.117, df = 1, P < 0.001). Among those with a history of depression, 74% had a current prescription for antidepressant medication, but 57% still had an elevated PHQ-9 score indicating possible undertreatment. STUDY 2: In 148 patients (mean age 70.3 ± 11.0 years, 39% female) the prevalence of screened depression was 28.4%, but only 3.3% had a documented history of depression suggesting significant underdiagnosis. Patients with depression were significantly more likely to die within 6 months of revascularization (9.5% vs. 0.9%; odds ratio 1.48, 95% confidence interval: 1.08 to 2.29). There was no association between depression and risk of length of stay, reintervention, or readmission. Conclusions Depression is underdiagnosed and undertreated among patients with PAD, which has grave consequences as it is associated with 1.5 times the odds of mortality within 6 months of revascularization. There is a critical need for more robust screenings and comprehensive mental health treatment for patients with concomitant depression and PAD. Among patients with peripheral artery disease (PAD), depression is diagnosed in 17–25% and negatively impacts wound healing, quality of life, and survival. We hypothesized that depression is underdiagnosed in patients with PAD. Additionally, given the associations between depression and mortality in PAD patients, there is an increased need to investigate the strength of this relationship. The present analysis includes 2 studies to address the following aims: (1) Investigation of the prevalence of concomitant PAD and depression in a cohort from the Southeastern United States, and (2) Examination of the association between depression and all-cause mortality in a cohort of Canadian patients with PAD. STUDY 1: From June–August 2022, the Patient Health Questionnaire Module 9 (PHQ-9) was administered to all patients seeking PAD-related care including medical, wound/podiatric, or vascular interventional/surgical treatment, in the University of North Carolina-Chapel Hill Vascular, Wound, and Podiatry clinics. The PHQ-9 assesses symptoms over 2 weeks and is scored 0–27, with higher scores indicating increasingly severe depression. Demographics, primary diagnosis, depression history, and antidepressant prescription were determined through chart review. We compared the proportion of positive depression screenings (PHQ-9 ≥ 5) to known depression. Among those treated for depression, the PHQ-9 score severity was evaluated. T-tests and χ2 tests were used to compare means and proportions. STUDY 2: From July 2015 to October 2016, the Geriatric Depression Scale Short Form was administered to adult patients with PAD undergoing revascularization. The Geriatric Depression Scale Short Form is a self-report measure of depression with a score >5 consistent with depression. The prevalence of depression was determined; primary outcome was all-cause mortality at 6 months. STUDY 1: In 104 PAD patients (mean age 66.6 ± 11.3 years, 37% female), 37% of respondents scored ≥5 on the PHQ-9 survey, indicating at least mild depression. Only 18% of PAD patients had a history of depression, demonstrating a significant difference between the PHQ-9 findings and documented medical history. While depression was underdiagnosed in both men and women, men were more likely to have unrecognized depression (chi-squared statistic = 35.117, df = 1, P < 0.001). Among those with a history of depression, 74% had a current prescription for antidepressant medication, but 57% still had an elevated PHQ-9 score indicating possible undertreatment. STUDY 2: In 148 patients (mean age 70.3 ± 11.0 years, 39% female) the prevalence of screened depression was 28.4%, but only 3.3% had a documented history of depression suggesting significant underdiagnosis. Patients with depression were significantly more likely to die within 6 months of revascularization (9.5% vs. 0.9%; odds ratio 1.48, 95% confidence interval: 1.08 to 2.29). There was no association between depression and risk of length of stay, reintervention, or readmission. Depression is underdiagnosed and undertreated among patients with PAD, which has grave consequences as it is associated with 1.5 times the odds of mortality within 6 months of revascularization. There is a critical need for more robust screenings and comprehensive mental health treatment for patients with concomitant depression and PAD." @default.
• W4328105353 created "2023-03-22" @default.
• W4328105353 creator A5000008870 @default.
• W4328105353 creator A5008742683 @default.
• W4328105353 creator A5025881908 @default.
• W4328105353 creator A5025983775 @default.
• W4328105353 creator A5082943365 @default.
• W4328105353 date "2023-09-01" @default.
• W4328105353 modified "2023-10-12" @default.
• W4328105353 title "Depression in Patients with Peripheral Artery Disease: An Underdiagnosis with Increased Mortality" @default.
• W4328105353 cites W102458143 @default.
• W4328105353 cites W176689803 @default.
• W4328105353 cites W1967885477 @default.
• W4328105353 cites W1989975854 @default.
• W4328105353 cites W1996333864 @default.
• W4328105353 cites W2007268652 @default.
• W4328105353 cites W2007805704 @default.
• W4328105353 cites W2011446619 @default.
• W4328105353 cites W2022347267 @default.
• W4328105353 cites W2036474992 @default.
• W4328105353 cites W2087074693 @default.
• W4328105353 cites W2125968053 @default.
• W4328105353 cites W2132322340 @default.
• W4328105353 cites W2159171283 @default.
• W4328105353 cites W2322333106 @default.
• W4328105353 cites W2332559082 @default.
• W4328105353 cites W25032932 @default.
• W4328105353 cites W2568164490 @default.
• W4328105353 cites W2792441257 @default.
• W4328105353 cites W2803871864 @default.
• W4328105353 cites W2804682422 @default.
• W4328105353 cites W2884062670 @default.
• W4328105353 cites W2970314365 @default.
• W4328105353 cites W2971888412 @default.
• W4328105353 cites W2975339514 @default.
• W4328105353 cites W3084325340 @default.
• W4328105353 cites W3160682093 @default.
• W4328105353 cites W4282827258 @default.
• W4328105353 cites W4297513222 @default.
• W4328105353 doi "https://doi.org/10.1016/j.avsg.2023.03.002" @default.
• W4328105353 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36948397" @default.
• W4328105353 hasPublicationYear "2023" @default.
• W4328105353 type Work @default.
• W4328105353 citedByCount "1" @default.
• W4328105353 countsByYear W43281053532023 @default.
• W4328105353 crossrefType "journal-article" @default.
• W4328105353 hasAuthorship W4328105353A5000008870 @default.
• W4328105353 hasAuthorship W4328105353A5008742683 @default.
• W4328105353 hasAuthorship W4328105353A5025881908 @default.
• W4328105353 hasAuthorship W4328105353A5025983775 @default.
• W4328105353 hasAuthorship W4328105353A5082943365 @default.
• W4328105353 hasConcept C118552586 @default.
• W4328105353 hasConcept C126322002 @default.
• W4328105353 hasConcept C139719470 @default.
• W4328105353 hasConcept C142724271 @default.
• W4328105353 hasConcept C150960172 @default.
• W4328105353 hasConcept C162324750 @default.
• W4328105353 hasConcept C1862650 @default.
• W4328105353 hasConcept C194828623 @default.
• W4328105353 hasConcept C204787440 @default.
• W4328105353 hasConcept C206179267 @default.
• W4328105353 hasConcept C2776760841 @default.
• W4328105353 hasConcept C2776867660 @default.
• W4328105353 hasConcept C2778213512 @default.
• W4328105353 hasConcept C2778529449 @default.
• W4328105353 hasConcept C2780844640 @default.
• W4328105353 hasConcept C3019858935 @default.
• W4328105353 hasConcept C558461103 @default.
• W4328105353 hasConcept C71924100 @default.
• W4328105353 hasConcept C72563966 @default.
• W4328105353 hasConceptScore W4328105353C118552586 @default.
• W4328105353 hasConceptScore W4328105353C126322002 @default.
• W4328105353 hasConceptScore W4328105353C139719470 @default.
• W4328105353 hasConceptScore W4328105353C142724271 @default.
• W4328105353 hasConceptScore W4328105353C150960172 @default.
• W4328105353 hasConceptScore W4328105353C162324750 @default.
• W4328105353 hasConceptScore W4328105353C1862650 @default.
• W4328105353 hasConceptScore W4328105353C194828623 @default.
• W4328105353 hasConceptScore W4328105353C204787440 @default.
• W4328105353 hasConceptScore W4328105353C206179267 @default.
• W4328105353 hasConceptScore W4328105353C2776760841 @default.
• W4328105353 hasConceptScore W4328105353C2776867660 @default.
• W4328105353 hasConceptScore W4328105353C2778213512 @default.
• W4328105353 hasConceptScore W4328105353C2778529449 @default.
• W4328105353 hasConceptScore W4328105353C2780844640 @default.
• W4328105353 hasConceptScore W4328105353C3019858935 @default.
• W4328105353 hasConceptScore W4328105353C558461103 @default.
• W4328105353 hasConceptScore W4328105353C71924100 @default.
• W4328105353 hasConceptScore W4328105353C72563966 @default.
• W4328105353 hasLocation W43281053531 @default.
• W4328105353 hasLocation W43281053532 @default.
• W4328105353 hasOpenAccess W4328105353 @default.
• W4328105353 hasPrimaryLocation W43281053531 @default.
• W4328105353 hasRelatedWork W2025097635 @default.
• W4328105353 hasRelatedWork W2131315637 @default.
• W4328105353 hasRelatedWork W2212224565 @default.
• W4328105353 hasRelatedWork W2276832413 @default.
• W4328105353 hasRelatedWork W2314119030 @default.

• next